Apr 28, 2022 / 02:30PM GMT
Mayank Mamtani - B. Riley Securities - Analyst
Hi, good morning. This is Mayank Mamtani, senior biotech analyst at B. Riley. I'm delighted to take off our next fireside chat with NGM Biopharmaceuticals. I'm pleased to have with me David Woodhouse, the CEO; and Siobhan, the CFO.
Questions and Answers:
Mayank Mamtani - B. Riley Securities - AnalystMaybe, David, if you could kick us off with providing the overview of your pipeline, very big pipeline, but the focus obviously is on ophthalmology today. And maybe also give us the details of the Merck collaboration you have around that.
David Woodhouse - NGM Biopharmaceuticals, Inc. - CEO
Sure, and thanks for having us today, Mayank. Yeah. Our biologics discovery platform -- so we have quite a broad pipeline. It spans liver, metabolic, oncology, and ophthalmology. We have seven programs, almost all of them in the clinic, or the last of those seven will go into clinic this quarter. But I understand today is on oncology -- or on ophthalmology.
And so our lead